Korean bio stocks struggle as series of scandals weigh down the category
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Bellwethers Samsung Biologics and Celltrion tanked by 3 to 5 percent Monday.
MedPacto remained in the negative territory, failing to recover from a nosedive of 28 percent last Thursday due to a setback in its pivotal oncology clinical trial last week.
Daewoong Pharmaceutical lost most of its earlier gains boosted by a success in a Phase 3 trial of a new diabetes drug last week.
The bearish trend in the sector is attributable to continuous adverse events that occurred during the first two weeks of this month amid the accelerated tightening of monetary policy around the world working unfavorably for growth stocks.
Lack of big license or M&A news from Korean names at this year¡¯s JP Morgan Healthcare Conference, the largest pharma trade show, was also a disappointment.
The conference was held online, and the overall vibe cooled with no major M&A news, said Heo Hye-min, a Kiwoom Securities researcher, adding license transactions during this year's JP Morgan Conference fell compared to last year due to slow M&A activity.
In the worst-case scenario, Celltrion stocks could be suspended from trading violations at Celltrion and Celltrion Healthcare amount to 98.5 billion won ($82.6 million) and 50.8 billion won, respectively.
Osstem Implant stocks were suspended from trading due to a charge of 221.5 won embezzlement, which is 108 percent of the company¡¯s equity capital, on Jan. 3. The company will receive a listing eligibility review on Jan. 24.
The accounting scandal of Samsung Biologics took five months for the financial authorities to come to a conclusion. Its stock was suspended for about a month from Nov. 15, 2018.
Stock exchange authorities will determine the fate of Sillajen on Jan. 18, whose stock trade have been suspended since May 4, 2020 due to breach of trust and embezzlement charges.
[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Korea Eximbank to finance $150 mn to Trafigura for stable base metal supply to Korea - Pulse by Maeil Business News Korea
- SRI bond issues in Korea nearly double last year to top $100 bn last year - Pulse by Maeil Business News Korea
- KT, Shinhan Bank enter $367 mn share swap deal for digitalization push - Pulse by Maeil Business News Korea
- Investors on the sidelines as they await the mega-arrival of LG Energy Solution - Pulse by Maeil Business News Korea
- Rent demand to challenge Korean banks in keeping household debt in check - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- K방산 아킬레스건은 [K-방산 : New Dream]
- NCT 태일, 불미스러운 일로 팀 탈퇴…SM “엄중함 인지”[공식입장][전문] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이